Effects of Esketamine on acute pain after coronary artery bypass grafting surgery a-single-center randomized double-blind control trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053437

Enrollment

Unknown

Registered

2021-11-21

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Group A:Remifentanil

Group B: Esketamine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients between the ages of 18 and 65 who are undergoing open sternotomy coronary artery bypass grafting under general anesthesia

Exclusion criteria

Exclusion criteria: 1. Those with known allergies and allergic constitution to the drug components in this study; 2. Have a history of general anesthesia allergy, opioid allergy, and non-steroidal drug allergy; 3. History of neurological disease; history of chronic pain; drug addiction and alcoholism; history of long-term opioid use 4. Organ dysfunction: chronic obstructive pulmonary disease (COPD) requiring oxygen therapy, bronchial asthma, heart failure, poor left ventricular function (EF28kg/m^2; 7. Language barriers, unable to complete the experiment according to the research protocol.

Design outcomes

Primary

Measure	Time frame
pain score;	—

Countries

China

Contacts

Public ContactXie Keliang

Tianjin Medical University General Hospital

mzk2011@126.com+86 15332112099

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026